Development Background Of Saxagliptin

  Development background of Saxagliptin

  The data show that nearly 290 million people worldwide currently have diabetes, of which type 2 diabetes is $number. Without stopping the spread of diabetes, the world's diabetes population will reach 440 million 2030 years ago, and diabetes has become the fourth most deadly disease in the world today.

  In the 1932, researchers discovered the human body's natural secretion of the gut-promoting hormone, which is secreted by the endocrine cells of the small intestine after ingestion, Saxagliptin which stimulates insulin secretion by pancreatic islet beta cells to reduce blood sugar. China Ministry of Health Diabetes Counseling and cardiovascular disease prevention and Treatment center experts, the PLA General Hospital Professor Pan introduced, in contrast to other drugs that simply promote insulin secretion, the role of intestinal-promoting glucagon-like hypoglycemic agents, which are glucose-dependent, only "directs" insulin production at elevated levels of blood sugar, thus protecting islet β cell function. A number of international studies have shown that the intestinal-stimulating hormone can not only promote insulin secretion in islet beta cells, reduce blood sugar, but also reduce the apoptosis of beta cells, thus delaying the progression of disease, and is expected to fundamentally curb the progression of type 2 diabetes.

  The unique hypoglycemic mechanism of intestinal gonadotropin accelerates the research and development process of new diabetes drugs. At present, Saxagliptin there are two kinds of drugs based on the mechanism of intestinal promoting function, but the mechanism is not identical. A class of analogues, supplemented by exogenous intestinal enhancers, enhances the intestinal stimulation of the diabetic patients by stimulating the secretion of insulin by beta cells, known as exogenous gut-promoting cytokines. The other is the DPP-4 (dipeptide) inhibitor, which is represented by Saxagliptin, called endogenous intestinal gonadotropin. The DPP-4 inhibitor was used to prolong the effect time of the patients ' gut-promoting hormone to reduce the sugar, and its side effect was very small and the medication was convenient. Saxagliptin The UKPDS data show that the function of islet beta cells has been lost in half when diagnosed with diabetes. Professor Yang Wenying, Vice president of the Asian Diabetes Association, says one important reason for the inability to effectively control hyperglycemia over time is that existing treatment regimens are not yet able to protect human islet beta cells in a lasting and effective manner. However, studies have shown that endogenous intestinal gonadotropin can significantly improve the function of β-cell in pancreatic islet while persistent hypoglycemic effect.